Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

The Role of Low Dose Whole Body CT in the Detection of Progression of Patients with Smoldering Multiple Myeloma

Maria Gavriatopoulou, Andriani Boultadaki, Vassilis Koutoulidis, MD, Ioannis Ntanasis-Stathopoulos, MD, Charis Bourgioti, Panagiotis Malandrakis, MD, Despina Fotiou, BMBS, MA, Magdalini Migkou, Nikolaos Kanellias, MD, Evangelos Eleutherakis-Papaiakovou, MD, Efstathios Kastritis, MD, Evangelos Terpos, MDPhD, Meletios A. Dimopoulos, MD, Lia A. Moulopoulos, MD

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-136256

Published: 2020

Journal Articles

A Prospective Study and Identification of Genomewide Association Markers of Familial Predisposition to Plasma Cell Dyscrasias

Adam S Sperling, MD PhD, Rebecca Georgakopoulou, MSc, Mehmet Kemal Samur, PhD, Christine Ivy Liacos, MSc, Brittany E Sandoval, MSc, Flora Zagouri, MD, Maria Gavriatopoulou, Evangelos Eleutherakis-Papaiakovou, MD, Magdalini Migkou, Nikolaos Kanellias, MD, Despina Fotiou, BMBS, MA, Ioannis Ntanasis-Stathopoulos, MD, Evangelos Terpos, MDPhD, Efstathios Kastritis, MD, Nikhil C. Munshi, MD, Meletios A Dimopoulos

Blood (2020) 136 (Supplement 1): 8.

https://doi.org/10.1182/blood-2020-137337

Published: 2020

Journal Articles

The Addition of IMiDs for Patients with Daratumumab-Refractory Multiple Myeloma Can Overcome Refractoriness to Both Agents

Despina Fotiou, BMBS, MA, Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, MD, Magdalini Migkou, Nikolaos Kanellias, MD, Panagiotis Malandrakis, MD, Foteini Theodorakakou, MD, Ioanna Dialoupi, MD, Evangelos Eleutherakis-Papaiakovou, MD, Maria Roussou, MD, Evangelos Terpos, MDPhD, Meletios A. Dimopoulos, MD, Efstathios Kastritis

Blood (2020) 136 (Supplement 1): 21.

https://doi.org/10.1182/blood-2020-136323

Published: 2020

Journal Articles

Short Daratumumab Consolidation in Patients with AL Amyloidosis or Lcdd Improves Complete Response Rates and Modifies Bone Marrow Microenvironment

Efstathios Kastritis, MD, Pantelis Roussakis, MSc, Ioannis V Kostopoulos, PhD, Foteini Theodorakakou, MD, Despina Fotiou, BMBS, MA, Nikolaos Kanellias, MD, Ioanna Dialoupi, MD, Magdalini Migkou, Maria Roussou, MD, Evangelos Eleutherakis-Papaiakovou, MD, Asimina Papanikolaou, MD, Anastasia Gatou, MD, Ourania E. Tsitsilonis, MD PhD, Maria Gavriatopoulou, Evangelos Terpos, MDPhD, Meletios A Dimopoulos

Blood (2020) 136 (Supplement 1): 25.

https://doi.org/10.1182/blood-2020-137353

Published: 2020

Journal Articles

Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) As a Biomarker of Renal Outcomes in AL Amyloidosis

Efstathios Kastritis, MD, Ioannis Papassotiriou, PhD, Foteini Theodorakakou, MD, Alexandra Margeli, PhD, Anastasia Barzteliotou, PhD, Eleni Tsiligkeridou, Amalia Andreatou, Despina Fotiou, BMBS, MA, Magdalini Migkou, Nikolaos Kanellias, MD, Ioanna Dialoupi, MD, Ioannis Ntanasis-Stathopoulos, MD, Panagiotis Malandrakis, MD, Maria Gavriatopoulou, Evangelos Terpos, MD PhD, Meletios A Dimopoulos

Blood (2020) 136 (Supplement 1): 33.

https://doi.org/10.1182/blood-2020-136774

Published: 2020

Journal Articles

Daratumumab with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment: Results on Efficacy and Safety of the Phase 2 Dare Study

Efstathios Kastritis, MD, Evangelos Terpos, MDPhD, Argiris Symeonidis, MD PhD, Sosana Delimpasi, MD, Michele Cavo, Elena Zamagni, Eirini Katodritou, MD, Elena Rivolti, MD, Marie-Christine Kyrtsonis, MD, Maria Gavriatopoulou, Maria Roussou, MD, Despina Fotiou, MD, Evdoxia Hatjiharissi, MD, Nikolaos Kanellias, MD, Magdalini Migkou, Meletios A Dimopoulos

Blood (2020) 136 (Supplement 1): 48–49.

https://doi.org/10.1182/blood-2020-140322

Published: 2020

Journal Articles

Protective Effects of Daratumumab on Carfilzomib-Related Cardiac Dysfunction in Patients with Relapsed Multiple Myeloma: Results from an Observational Study

Blood (2020) 136 (Supplement 1): 17.

https://doi.org/10.1182/blood-2020-137169

Published: 2020

Journal Articles

IMiD Retreatment in Patients Refractory to Both an IMiD and an Anti-CD38 Antibody Induces Significant Response Rates Post Anti-CD38 Exposure

Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, MD, Panagiotis Malandrakis, MD, Despina Fotiou, MD, Magdalini Migkou, Nikolaos Kanellias, MD, Evangelos Eleutherakis-Papaiakovou, MD, Ioanna Dialoupi, MD, Foteini Theodorakakou, MD, Maria Roussou, MD, Evangelos Terpos, MD PhD, Efstathios Kastritis, MD, Meletios A. Dimopoulos, MD

Blood (2020) 136 (Supplement 1): 12.

https://doi.org/10.1182/blood-2020-136248

Published: 2020

Journal Articles

Clinical Impact of an Early Response and of Early Initiation of Salvage Therapy in Patients with Systemic Light Chain (AL) Amyloidosis

Eftathios Kastritis, Maria Gavriatopoulou, MD, Maria Roussou, MD, Magdalini Migkou, MD, Despina Fotiou, BMBS, MA, Ioanna Dialoupi, MD, Nikolaos Kanellias, MD, Evangelos Eleutherakis-Papaiakovou, MD, Foteini Theodorakakou, MD, Asimina Papanikolaou, MD, Erasmia Psimenou, MD, Kimon Stamatelopoulos, MD, Efstathios Manios, MD, Maria Irini Tselegkidi, MD, Argyrios Ntalianis, MD, Stavroula Giannouli, MD PhD, Evangelos Terpos, MD PhD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 1894.

https://doi.org/10.1182/blood-2019-128208

Published: 2019

Journal Articles

Renal Pathology in Patients with Monoclonal Gammopathy or Multiple Myeloma: Monoclonal Immunoglobulins Are Not Always the Cause

Eftathios Kastritis, Nikolaos Kanellias, MD, Foteini Theodorakakou, MD, Erasmia Psimenou, MD, Charikleia Gakiopoulou, MD, Smaragdi Marinaki, Maria Roussou, MD, Maria Gavriatopoulou, MD, Magdalini Migkou, MD, Evangelos Eleutherakis-Papaiakovou, MD, Panagiotis Malandrakis, MD, Evangelos Terpos, MD PhD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 1776.

https://doi.org/10.1182/blood-2019-126385

Published: 2019

Journal Articles

Pulmonary Function Tests Reveal Unrecognized Lung Dysfunction and Have Independent Prognostic Significance in Patients with Systemic AL Amyloidosis

Eftathios Kastritis, Georgia Trakada, MD, Despina Fotiou, BMBS, MA, Magdalini Migkou, MD, Maria Gavriatopoulou, MD, Nikolaos Kanellias, MD, Evangelos Eleutherakis-Papaiakovou, MD, Ioanna Dialoupi, MD, Ioannis Ntanasis-Stathopoulos, MD, Despina Mparmparousi, Aikaterini Xirokosta, Evangelos Terpos, MD PhD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 1842.

https://doi.org/10.1182/blood-2019-125877

Published: 2019

Journal Articles

Serum Neutrophil Gelatinase-Associated Lipocalin Independently Predicts for Renal Response in Myeloma Patients with Severe Renal Impairment

Meletios A. Dimopoulos, MD, Maria Roussou, MD, Eftathios Kastritis, Alexandra Margeli, PhD, Evangelos Eleutherakis-Papaiakovou, MD, Ioannis Ntanasis-Stathopoulos, MD, Nikolaos Kanellias, MD, Gerasimos-Petros Papassotiriou, PhD, Despina Fotiou, MD, Magdalini Migkou, MD, Maria Gavriatopoulou, MD, Erasmia Psimenou, MD, Ioannis Papassotiriou, PhD, Evangelos Terpos, MD PhD

Blood (2019) 134 (Supplement_1): 1877.

https://doi.org/10.1182/blood-2019-123912

Published: 2019

Journal Articles

Next Generation Flow Cytometry Provides a Standardized, Highly Sensitive and Informative Method for the Analysis of Circulating Plasma Cells in Newly Diagnosed Multiple Myeloma: A Single Center Study in 182 Patients

Evangelos Terpos, MD PhD, Ioannis V. Kostopoulos, Aristea-Maria Papanota, MD, Konstantinos Papadimitriou, BSc, Panagiotis Malandrakis, MD, Paraskevi Micheli, BSc, Ioannis Ntanasis-Stathopoulos, MD, Despina Fotiou, MD, Andreas Metousis, BSc, Nikolaos Kanellias, MD, Magdalini Migkou, MD, Evangelos Eleutherakis-Papaiakovou, MD, Maria Gavriatopoulou, MD, Eftathios Kastritis, Ourania E. Tsitsilonis, MD PhD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 4338.

https://doi.org/10.1182/blood-2019-127989

Published: 2019

Journal Articles

Natural History of Skeletal Related Events in Patients with Multiple Myeloma Who Received First- and Second- Line Therapy with Novel Agents: Results from a Single Center Analysis in 620 Patients

Evangelos Terpos, MD PhD, Nikolaos Kanellias, MD, Eftathios Kastritis, Maria Gavriatopoulou, MD, Vassilis Koutoulidis, MD, Ioannis Ntanasis-Stathopoulos, MD, Aristea-Maria Papanota, MD, Despina Fotiou, MD, Magdalini Migkou, MD, Evangelos Eleutherakis-Papaiakovou, MD, Panagiotis Malandrakis, MD, Tina Bagratuni, PhD, Maria Roussou, MD, Lia A. Moulopoulos, MD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 4326.

https://doi.org/10.1182/blood-2019-123606

Published: 2019

Journal Articles

Primary Bone Non-Hodgkin's Lymphoma: A Specific Clinical Entity with Aggressive Clinical Course and High Cure Rate - Retrospective Analysis of 102 Patients from Greece

Argiris Symeonidis, MD PhD, Sotirios Papageorgiou, MD PhD, Antonis Patrinos, MD, Maria Melachrinou, MD PhD, Alexandra Kourakli, MD PhD, Vassiliki Pappa, MD, Maria K. Angelopoulou, MD, Anastasia Sioni, Nikolaos Kanellias, MD, Sofia Chatzileontiadou, MD, Eleftheria Hatzimichael, Panagiotis Zikos, Anastasia Pouli, MD PhD, Maria Papaioannou, Evangelos Terpos, MD PhD, Gerasimos Pangalis, MD, Theodoros P. Vassilakopoulos, MD PhD

Blood (2019) 134 (Supplement_1): 5340.

https://doi.org/10.1182/blood-2019-130219

Published: 2019

Journal Articles

Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Is a Renal Biomarker with Potential Clinical Applications in Monoclonal Gammopathy of Renal Significance (MGRS)

Eftathios Kastritis, Ioannis Papassotiriou, PhD, Maria Roussou, MD, Maria Gavriatopoulou, MD, Mantzou Aimilia, PhD, Erasmia Psimenou, MD, Smaragdi Marinaki, Charikleia Gakiopoulou, MD, Alexandra Margeli, PhD, Nikolaos Kanellias, MD, Magdalini Migkou, MD, Despina Fotiou, BMBS, MA, Ioannis Ntanasis-Stathopoulos, MD, Gerasimos-Petros Papassotiriou, PhD, Aristea-Maria Papanota, MD, Evangelos Terpos, MD PhD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 3126.

https://doi.org/10.1182/blood-2019-125305

Published: 2019

Journal Articles

The Clinical Significance of a Novel microRNA Signature in Multiple Myeloma

Pinelopi I Artemaki, BSc, Aristea-Maria Papanota, MD, Paraskevi Karousi, BSc, Christine Liacos, MSc, Christos K. Kontos, PhD, Dimitris Patseas, BSc, Maria-Alexandra Papadimitriou, BSc, Evangelos Eleutherakis-Papaiakovou, MD, Margaritis Avgeris, PhD, Nikolaos Kanellias, MD, Tina Bagratuni, PhD, Maria Roussou, MD, Ioanna Dialoupi, MD, Eftathios Kastritis, Maria Gavriatopoulou, MD, Meletios A. Dimopoulos, MD, Andreas Scorilas, PhD, Evangelos Terpos, MD PhD

Blood (2019) 134 (Supplement_1): 5529.

https://doi.org/10.1182/blood-2019-129218

Published: 2019

Journal Articles

Efficacy of Daratumumab with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment: An Interim Analysis of a Phase 2 Study (the DARE Study)

Eftathios Kastritis, Evangelos Terpos, MD PhD, Argiris Symeonidis, MD PhD, Sosana Delimpasi, MD, Michele Cavo, Elena Zamagni, MD, Eirini Katodritou, MD, Barbara Gamberi, MD, Marie-Christine Kyrtsonis, MD PhD, Maria Gavriatopoulou, MD, Maria Roussou, MD, Despina Fotiou, MD, Evdoxia Hatjiharissi, Nikolaos Kanellias, MD, Magdalini Migkou, MD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 1881.

https://doi.org/10.1182/blood-2019-124630

Published: 2019

Journal Articles

Consolidation with Carfilzomib, Lenalidomide and Dexamethasone (KRd) Following ASCT Results in High Rates of Minimal Residual Disease Negativity and Improves Bone Metabolism, in the Absence of Bisphosphonates, Among Newly Diagnosed Patients with Multiple Myeloma

Maria Gavriatopoulou, MD, Evangelos Terpos, MD PhD, Ioannis Ntanasis-Stathopoulos, MD, Panagiotis Malandrakis, MD, Evangelos Eleutherakis-Papaiakovou, MD, Athanasios Papatheodorou, PhD, Nikolaos Kanellias, MD, Magdalini Migkou, MD, Despina Fotiou, MD, Ioanna Dialoupi, MD, Maria Roussou, MD, Nikoletta-Aikaterini Kokkali, Eftathios Kastritis, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 3118.

https://doi.org/10.1182/blood-2019-123916

Published: 2019

Journal Articles

Primary Treatment of Light Chain (AL) Amyloidosis with Bortezomib, Lenalidomide and Dexamethasone (VRD)

Blood (2018) 132 (Supplement 1): 3248.

https://doi.org/10.1182/blood-2018-99-111608

Published: 2018

NARROW

The Role of Low Dose Whole Body CT in the Detection of Progression of Patients with Smoldering Multiple Myeloma

A Prospective Study and Identification of Genomewide Association Markers of Familial Predisposition to Plasma Cell Dyscrasias

The Addition of IMiDs for Patients with Daratumumab-Refractory Multiple Myeloma Can Overcome Refractoriness to Both Agents

Short Daratumumab Consolidation in Patients with AL Amyloidosis or Lcdd Improves Complete Response Rates and Modifies Bone Marrow Microenvironment

Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) As a Biomarker of Renal Outcomes in AL Amyloidosis

Daratumumab with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment: Results on Efficacy and Safety of the Phase 2 Dare Study

Protective Effects of Daratumumab on Carfilzomib-Related Cardiac Dysfunction in Patients with Relapsed Multiple Myeloma: Results from an Observational Study

IMiD Retreatment in Patients Refractory to Both an IMiD and an Anti-CD38 Antibody Induces Significant Response Rates Post Anti-CD38 Exposure

Clinical Impact of an Early Response and of Early Initiation of Salvage Therapy in Patients with Systemic Light Chain (AL) Amyloidosis

Renal Pathology in Patients with Monoclonal Gammopathy or Multiple Myeloma: Monoclonal Immunoglobulins Are Not Always the Cause

Pulmonary Function Tests Reveal Unrecognized Lung Dysfunction and Have Independent Prognostic Significance in Patients with Systemic AL Amyloidosis

Serum Neutrophil Gelatinase-Associated Lipocalin Independently Predicts for Renal Response in Myeloma Patients with Severe Renal Impairment

Next Generation Flow Cytometry Provides a Standardized, Highly Sensitive and Informative Method for the Analysis of Circulating Plasma Cells in Newly Diagnosed Multiple Myeloma: A Single Center Study in 182 Patients

Natural History of Skeletal Related Events in Patients with Multiple Myeloma Who Received First- and Second- Line Therapy with Novel Agents: Results from a Single Center Analysis in 620 Patients

Primary Bone Non-Hodgkin's Lymphoma: A Specific Clinical Entity with Aggressive Clinical Course and High Cure Rate - Retrospective Analysis of 102 Patients from Greece

Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Is a Renal Biomarker with Potential Clinical Applications in Monoclonal Gammopathy of Renal Significance (MGRS)

The Clinical Significance of a Novel microRNA Signature in Multiple Myeloma

Efficacy of Daratumumab with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment: An Interim Analysis of a Phase 2 Study (the DARE Study)

Consolidation with Carfilzomib, Lenalidomide and Dexamethasone (KRd) Following ASCT Results in High Rates of Minimal Residual Disease Negativity and Improves Bone Metabolism, in the Absence of Bisphosphonates, Among Newly Diagnosed Patients with Multiple Myeloma

Primary Treatment of Light Chain (AL) Amyloidosis with Bortezomib, Lenalidomide and Dexamethasone (VRD)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only